Ms. Iris Bincovich reports

FDA CENTER FOR VETERINARY MEDICINE GRANTS INNOCAN A FEE WAIVER IN 2026 FOR THE THIRD CONSECUTIVE TIME

The U.S. Food and Drug Administration's (FDA) Center for Veterinary Medicine (CVM) has granted Innocan Pharma Corp. a sponsor fee waiver for its LPT-CBD (liposome platform technology-cannabidiol) product for the third consecutive year.

The FDA's CVM assesses annual fees for animal drug applications. Sponsors developing innovative products may request a fee waiver each year under the "significant barrier to innovation" provision. Accordingly, every year, Innocan submits an annual renewal request that includes a brief update on development progress and forward plans. Following review of the company's latest submission, CVM has again granted Innocan a fee waiver for the year 2026. This represents the company's third consecutive annual waiver, underscoring CVM's continued recognition of Innocan's innovation-driven animal health program.

The waiver relates to the company's LPT-CBD drug product candidate, being developed as a subcutaneous injection for the management of chronic pain in dogs. In a blinded, crossover study conducted on osteoarthritic dogs, LPT-CBD demonstrated a statistically significant reduction in pain and meaningful improvements in overall well-being compared with placebo (empty liposomes). Together with additional studies previously conducted in osteoarthritic dogs, these results provide robust evidence supporting LPT-CBD's analgesic potential and its suitability as a treatment option for chronic pain in dogs.

"The veterinary market is open to new drug technologies that can address the limitations of current pain medications and offer a new alternative therapy," said Dr. Antonio Benitz, Innocan's animal health adviser. The fee waiver granted by CVM for the third time, recognizing LPT-CBD's innovation, reinforces Innocan's progress toward delivering a new solution for chronic pain in dogs.

Dr. Eyal Kalo, vice-president of research and development at Innocan, added: "U.S. pet ownership continues to grow, with an estimated 94 million households owning at least one pet. "Our technology is designed to meet rising demand for safe, effective chronic pain solutions, combining demonstrated therapeutic potential with the convenience of a single, once-monthly administration."

About Innocan Pharma Corp.

Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded (cannabidiol) liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60-per-cent-owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted on-line sales.

We seek Safe Harbor.